• UGI USER
  • May 17, 2024
  • 12 Likes
  • 1 Comments

SERIOUS ADVERSE EVENTS MAY OCCUR IN 1% OF COVAXIN RECIPIENTS

Why in the news?

  • A study published in Springer Nature highlights that adolescent girls and individuals with co-morbidities are at increased risk of adverse events after receiving Bharat Biotech’s Covexin (BBV152) vaccine.
  • Nearly one-third of participants in the observational study reported adverse events of special interest (AESI).
  • Conducted by Banaras Hindu University, the study titled “Long-term safety analysis of the BBV152 coronavirus vaccine in adolescents and adults” involved 1,024 participants.
source:toi

About Bharat Biotech:

  • Bharat Biotech International Limited (BBIL) is an Indian multinational biotechnology company.
  • Headquartered: in Hyderabad.
  • Engaged in drug discovery, development, and manufacturing.
  • Specialises in vaccines, biotherapeutics, pharmaceuticals, and healthcare products.
About  (BBV152) Covaxin vaccine:

  • Covaxin: India’s first indigenous whole-virion inactivated vaccine.
  • Developed by Bharat Biotech with Indian Medical Research Council(ICMR) and National Institute Of Virology(NIV).
  • Formulated with Algel-IMDG adjuvant for effective immune response without harm.Retains pathogen structure for immune recognition and response.
  • Targets spike protein and nucleocapsid protein for broader immunity.
  • Approval enhances India’s vaccine arsenal amid evolving pandemic challenges.

About Central Drugs Standard Control Organisation (CDSCO):

  • Under Directorate General of Health Services, Ministry of Health & Family Welfare
  • National Regulatory Authority (NRA) of India
  • Responsibilities: Approval of drugs, conduct of clinical trials, setting drug standards
  • Headquarters: New Delhi

Associated Article:

https://universalinstitutions.com/incovacc-intranasal-covid-19-vaccine/

https://universalinstitutions.com/from-jun-21-the-central-government-is-providing-75-of-vaccines-at-free-of-cost-to-the-state-governments-to-enhance-vaccination-program-in-this-hindsight-explain-the-covid-19-vaccination-program-in-i/